8-K

Poseida Therapeutics, Inc.

Date: December 11, 2023

/s/ Harry J. Leonhardt, Esq.

Name:

Title:

Harry J. Leonhardt, Esq.

General Counsel, Chief Compliance Officer &
Corporate Secretary

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2023

Poseida Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39376

47-2846548

(State or Other Jurisdiction
of Incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)


9390 Towne Centre Drive, Suite 200
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 779-3100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

PSTX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On December 10, 2023, Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing that members of its scientific research team and external advisors are providing an update on the Company’s research and development programs, including the Company’s Phase 1 clinical trial of P-BCMA-ALLO1. The Company presented several posters at the 65^th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in San Diego, California from December 9-12, 2023. A copy of the press release and one of the posters that was presented are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this report.

The information in this Item 7.01 of this report (including Exhibit 99.1 and Exhibit 99.2) is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release of Poseida Therapeutics, Inc., dated December 10, 2023.

99.2		Poster: Early Safety and Efficacy Results of P-BCMA-ALLO1, A Fully Allogeneic Chimeric Antigen Receptor T-cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM).

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Poseida Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits